While Express Scripts (ESRX), the largest pharmacy benefit manager in the country, has a firm grip on its industry, investors have been more concerned with getting a grip on the company's prospects for the future, especially after a negative outlook sent shares south late last year. In the following video, Motley Fool health care bureau chief quickly runs through his assessment of Express Scripts' guidance and discusses a few tailwinds and headwinds facing the company in the near future.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
What You Need to Know About Express Scripts' Earnings
NASDAQ: ESRX
Express Scripts Holding Company

The largest pharmacy benefit manager put up better than expected guidance.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Express Scripts and UnitedHealth Group. The Motley Fool owns shares of Express Scripts. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned


*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.